Monitoring for QTc Prolongation in Patients Receiving Sertraline

Introduction to QTc Prolongation Monitoring

• The European Heart Journal recommends repeating ECG after 2 weeks of treatment when restarting medications known to prolong the QT interval 1
• The American Heart Association states that monitoring should continue until drug levels stabilize and evidence of QT prolongation is no longer present 2

Recommended ECG Monitoring Schedule

• Baseline ECG should be performed before restarting sertraline, with repeat ECG at 1-2 weeks after achieving therapeutic dosing, and a second follow-up ECG at 1 month to ensure stability 1, 3

Critical QTc Thresholds

• The European Heart Journal and other guidelines suggest stopping sertraline immediately if QTc exceeds 500 ms, as this is considered an unequivocal risk threshold 4, 5
• A QTc increase of more than 60 ms from baseline is considered a clinically significant change, warranting immediate attention 1, 5

Risk Mitigation Strategies

• Before each ECG, ensure serum potassium levels are greater than 4 mmol/L and magnesium levels are greater than 2 mmol/L to minimize the risk of QTc prolongation 5
• Review all concomitant medications for QT-prolonging potential and avoid combining sertraline with other QT-prolonging drugs 1, 3, 5